Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024)
Fulcrum Therapeutics (FULC) posted quarterly FCF Margin of 73.62% for Q2 2024, up 245771.0% year-over-year from N/an in Q3 2023, and up 102.76% quarter-over-quarter from 2667.62% in Q4 2023.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported FCF Margin for 5 consecutive years, with 73.62% the latest figure, recorded in Q2 2024.
- In Q2 2024, FCF Margin rose 245771.0% year-over-year to 73.62%; the TTM figure through Jun 2025 stood at 81.53% (down 6607.0% YoY), while the FY2024 annual figure was 3.12%, up 325795.0% from the prior year.
- FCF Margin grew to 73.62% in Q2 2024 per FULC's latest filing, from 2667.62% in the prior quarter.
- Across five years, FCF Margin topped out at 73.62% in Q2 2024 and bottomed at 8232.88% in Q1 2023.
- Historically, FCF Margin has averaged 1712.24% across 5 years, with a median of 885.53% in 2022.
- Annual changes were most pronounced in 2023 — FCF Margin tumbled 734735 bps — and 2024, when it soared 245771 bps.
- Fulcrum Therapeutics' FCF Margin stood at 480.43% in 2020, then climbed by 8 bps to 442.41% in 2021, then sank by 554 bps to 2892.26% in 2022, then climbed by 8 bps to 2667.62% in 2023, then jumped by 103 bps to 73.62% in 2024.
- Business Quant data shows FULC's FCF Margin at 73.62% in Q2 2024, 2667.62% in Q4 2023, and 3026.48% in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 73.62% |
| Dec 31, 2023 | -2,667.62% |
| Sep 30, 2023 | -3,026.48% |
| Jun 30, 2023 | -2,384.09% |
| Mar 31, 2023 | -8,232.88% |
| Dec 31, 2022 | -2,892.26% |
| Sep 30, 2022 | -2,380.81% |
| Jun 30, 2022 | -1,492.19% |
| Mar 31, 2022 | -885.53% |
| Dec 31, 2021 | -442.41% |
| Sep 30, 2021 | -464.84% |
| Jun 30, 2021 | -419.68% |
| Mar 31, 2021 | -344.29% |
| Dec 31, 2020 | -480.43% |
| Sep 30, 2020 | -248.76% |
| Jun 30, 2020 | -716.55% |
| Mar 31, 2020 | -2,102.80% |